Abstract
The epidermal growth factor receptor (EGFR) is commonly expressed in colorectal cancer and is widely recognized as an important therapeutic target for this disease. The EGFRtargeting immunoglobulin IgG1 monoclonal antibody, cetuximab, and the IgG2 monoclonal antibody, panitumumab, are both approved in patients with metastatic colorectal cancer (mCRC). Cetuximab has been shown to be active as well as single agent as in combination with irinotecan in patients with chemorefractory metastatic colorectal cancer [1]. Panitumumab has been shown to be active as single agent in chemorefractory mCRC [2]. The activity of cetuximab in combination with irinotecan- and oxaliplatin-based therapy in the first-line setting has been demonstrated in phase II studies and in the randomized phase III study (Crystal study) [3–5].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
